# GUARD-01 (NCT05723991)

> Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05723991
- Phase: PHASE4
- Status: UNKNOWN
- Sponsor: Chunguang yang (101937)
- Conditions: Radical Cystectomy; Urothelial Carcinoma
- Interventions: Disitamab Vedotin and Gemcitabine
- Enrollment: 36
- Primary outcome: Pathologic Complete Response

## Indexed commentary on GUARD-01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=guard-01-nct05723991